Please Wait.....
Report
Generics BRIC (Brazil, Russia, India, China) Industry Guide 2020-2029
Industry Report I 2025-12-24 I 256 Pages I MarketLine
Generics BRIC (Brazil, Russia, India, China) Industry Guide 2020-2029
Summary
The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $1,84,072.7 million in 2024. China was the fastest growing country with a CAGR of 15.3% over the 2020-24 period.
- Within the generics industry, China is the leading country among the BRIC nations with market revenues of $1,27,482.1 million in 2024. This was followed by India, Brazil and Russia with a value of $36,628.0, $10,309.1, and $9,653.5 million, respectively.
- China is expected to lead the generics industry in the BRIC nations with a value of $1,95,272.1 million in 2029, followed by India, Brazil, Russia with expected values of $45,379.6, $13,858.9 and $13,825.7 million, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
- Leading company profiles reveal details of key generics market players' BRIC operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
- Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
Reasons to Buy
- What was the size of the BRIC generics market by value in 2024?
- What will be the size of the BRIC generics market in 2029?
- What factors are affecting the strength of competition in the BRIC generics market?
- How has the market performed over the last five years?
- How large is the BRIC generics market in relation to its regional counterparts?
Table of Contents
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 BRIC Generics
2.1. Industry Outlook
3 Generics in Brazil
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Generics in China
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Generics in India
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Generics in Russia
9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
10 Macroeconomic Indicators
10.1. Country data
11 Company Profiles
11.1. Sun Pharmaceutical Industries Ltd
11.2. Viatris Inc
11.3. Novartis AG
11.4. Teva Pharmaceutical Industries Ltd
11.5. Sandoz Group AG
11.6. Hikma Pharmaceuticals Plc
11.7. Sanofi
11.8. Les Laboratoires Servier SAS
11.9. Stada Arzneimittel AG
11.10. Bayer AG
11.11. Lupin Ltd
11.12. Aspen Pharmacare Holdings Ltd
11.13. EMS SA
11.14. Eurofarma Laboratorios SA
11.15. Ache Laboratorios Farmaceuticos SA
11.16. Sino Biopharmaceutical Ltd
11.17. Hansoh Pharmaceutical Group Co Ltd
11.18. CSPC Pharmaceutical Group Ltd
11.19. Dr. Reddy's Laboratories Ltd
11.20. Cipla Ltd
11.21. Aurobindo Pharma Ltd
11.22. PT Indofarma Tbk
11.23. PT Sanbe Farma
11.24. PT Kalbe Farma Tbk
11.25. PT Soho Global Health Tbk
11.26. Friulchem SpA
11.27. DOC Generici SRL
11.28. Recordati SpA
11.29. Daiichi Sankyo Co Ltd
11.30. Sawai Group Holdings Co Ltd
11.31. Toho Holdings Co Ltd
11.32. Towa Pharmaceutical Co Ltd
11.33. Laboratorios Silanes SA de CV
11.34. Pfizer Inc
11.35. Bluefish Pharmaceuticals AB
11.36. AstraZeneca Plc
11.37. Navamedic ASA
11.38. Beacons Pharmaceuticals Pte Ltd
11.39. Abbott Laboratories SA
11.40. Adcock Ingram Holdings Ltd
11.41. Dongkook Pharmaceutical Co Ltd
11.42. JW Holdings Corp
11.43. Hanmi Pharmaceuticals Co Ltd
11.44. Dong Wha Pharma Co Ltd
11.45. Esteve Pharmaceuticals SA
11.46. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
11.47. Deva Holding AS
11.48. Apotex Inc
11.49. Pharmstandard
11.50. Biocad
11.51. R-Pharm
12 Appendix
12.1. Methodology
12.2. About MarketLine
List of Tables
Table 1: BRIC generics industry, revenue($m), 2020-29
Table 2: BRIC generics industry, revenue($m), 2020-24
Table 3: BRIC generics industry, revenue($m), 2024-29
Table 4: Brazil generics market value: $ million, 2019-24
Table 5: Brazil generics market volume: % of total pharma volume, 2019-24
Table 6: Brazil generics market geography segmentation: $ million, 2024
Table 7: Brazil generics market value forecast: $ million, 2024-29
Table 8: Brazil generics market volume forecast: % of total pharma volume, 2024-29
Table 9: Brazil Size of Population (Million), 2020-24
Table 10: Brazil Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 11: Brazil GDP (Current Prices, $ Billion), 2020-24
Table 12: Brazil Inflation, 2020-24
Table 13: Brazil Consumer Price Index (Absolute), 2020-24
Table 14: Brazil Exchange Rate, 2019-24
Table 15: China generics market value: $ million, 2019-24
Table 16: China generics market volume: % of total pharma volume, 2019-24
Table 17: China generics market geography segmentation: $ million, 2024
Table 18: China generics market value forecast: $ million, 2024-29
Table 19: China generics market volume forecast: % of total pharma volume, 2024-29
Table 20: China Size of Population (Million), 2020-24
Table 21: China Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 22: China GDP (Current Prices, $ Billion), 2020-24
Table 23: China Inflation, 2020-24
Table 24: China Consumer Price Index (Absolute), 2020-24
Table 25: China Exchange Rate, 2019-24
Table 26: India generics market value: $ million, 2019-24
Table 27: India generics market volume: % of total pharma volume, 2019-24
Table 28: India generics market geography segmentation: $ million, 2024
Table 29: India generics market value forecast: $ million, 2024-29
Table 30: India generics market volume forecast: % of total pharma volume, 2024-29
Table 31: India Size of Population (Million), 2020-24
Table 32: India Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 33: India GDP (Current Prices, $ Billion), 2020-24
Table 34: India Inflation, 2020-24
Table 35: India Consumer Price Index (Absolute), 2020-24
Table 36: India Exchange Rate, 2019-24
Table 37: Russia generics market value: $ million, 2019-24
Table 38: Russia generics market volume: % of total pharma volume, 2019-24
Table 39: Russia generics market geography segmentation: $ million, 2024
Table 40: Russia generics market value forecast: $ million, 2024-29
Table 41: Russia generics market volume forecast: % of total pharma volume, 2024-29
Table 42: Russia Size of Population (Million), 2020-24
Table 43: Russia Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 44: Russia GDP (Current Prices, $ Billion), 2020-24
Table 45: Russia Inflation, 2020-24
Table 46: Russia Consumer Price Index (Absolute), 2020-24
Table 47: Russia Exchange Rate, 2019-24
Table 48: Sun Pharmaceutical Industries Ltd: Key Facts
Table 49: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 50: Sun Pharmaceutical Industries Ltd: Key Employees
Table 51: Viatris Inc: Key Facts
Table 52: Viatris Inc: Annual Financial Ratios
Table 53: Viatris Inc: Key Employees
Table 54: Novartis AG: Key Facts
Table 55: Novartis AG: Annual Financial Ratios
Table 56: Novartis AG: Key Employees
Table 57: Teva Pharmaceutical Industries Ltd: Key Facts
Table 58: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 59: Teva Pharmaceutical Industries Ltd: Key Employees
Table 60: Sandoz Group AG: Key Facts
Table 61: Sandoz Group AG: Annual Financial Ratios
Table 62: Sandoz Group AG: Key Employees
Table 63: Hikma Pharmaceuticals Plc: Key Facts
Table 64: Hikma Pharmaceuticals Plc: Annual Financial Ratios
Table 65: Hikma Pharmaceuticals Plc: Key Employees
Table 66: Sanofi: Key Facts
Table 67: Sanofi: Annual Financial Ratios
Table 68: Sanofi: Key Employees
Table 69: Sanofi: Key Employees Continued
Table 70: Les Laboratoires Servier SAS: Key Facts
Table 71: Les Laboratoires Servier SAS: Key Employees
Table 72: Stada Arzneimittel AG: Key Facts
Table 73: Stada Arzneimittel AG: Key Employees
Table 74: Bayer AG: Key Facts
Table 75: Bayer AG: Annual Financial Ratios
Table 76: Bayer AG: Key Employees
Table 77: Bayer AG: Key Employees Continued
Table 78: Bayer AG: Key Employees Continued
Table 79: Lupin Ltd: Key Facts
Table 80: Lupin Ltd: Annual Financial Ratios
Table 81: Lupin Ltd: Key Employees
Table 82: Aspen Pharmacare Holdings Ltd: Key Facts
Table 83: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 84: Aspen Pharmacare Holdings Ltd: Key Employees
Table 85: EMS SA: Key Facts
Table 86: EMS SA: Key Employees
Table 87: Eurofarma Laboratorios SA: Key Facts
Table 88: Eurofarma Laboratorios SA: Key Employees
Table 89: Ache Laboratorios Farmaceuticos SA: Key Facts
Table 90: Ache Laboratorios Farmaceuticos SA: Key Employees
Table 91: Sino Biopharmaceutical Ltd: Key Facts
Table 92: Sino Biopharmaceutical Ltd: Annual Financial Ratios
Table 93: Sino Biopharmaceutical Ltd: Key Employees
Table 94: Hansoh Pharmaceutical Group Co Ltd: Key Facts
Table 95: Hansoh Pharmaceutical Group Co Ltd: Annual Financial Ratios
Table 96: Hansoh Pharmaceutical Group Co Ltd: Key Employees
Table 97: CSPC Pharmaceutical Group Ltd: Key Facts
Table 98: CSPC Pharmaceutical Group Ltd: Annual Financial Ratios
Table 99: CSPC Pharmaceutical Group Ltd: Key Employees
Table 100: Dr. Reddy's Laboratories Ltd: Key Facts
Table 101: Dr. Reddy's Laboratories Ltd: Annual Financial Ratios
Table 102: Dr. Reddy's Laboratories Ltd: Key Employees
Table 103: Cipla Ltd: Key Facts
Table 104: Cipla Ltd: Annual Financial Ratios
Table 105: Cipla Ltd: Key Employees
Table 106: Aurobindo Pharma Ltd: Key Facts
Table 107: Aurobindo Pharma Ltd: Annual Financial Ratios
Table 108: Aurobindo Pharma Ltd: Key Employees
Table 109: Aurobindo Pharma Ltd: Key Employees Continued
Table 110: PT Indofarma Tbk: Key Facts
Table 111: PT Indofarma Tbk: Annual Financial Ratios
Table 112: PT Sanbe Farma: Key Facts
Table 113: PT Sanbe Farma: Key Employees
Table 114: PT Kalbe Farma Tbk: Key Facts
Table 115: PT Kalbe Farma Tbk: Annual Financial Ratios
Table 116: PT Kalbe Farma Tbk: Key Employees
Table 117: PT Soho Global Health Tbk: Key Facts
Table 118: PT Soho Global Health Tbk: Annual Financial Ratios
Table 119: PT Soho Global Health Tbk: Key Employees
Table 120: Friulchem SpA: Key Facts
Table 121: Friulchem SpA: Key Employees
Table 122: DOC Generici SRL: Key Facts
Table 123: DOC Generici SRL: Key Employees
Table 124: Recordati SpA: Key Facts
Table 125: Recordati SpA: Annual Financial Ratios
Table 126: Recordati SpA: Key Employees
Table 127: Daiichi Sankyo Co Ltd: Key Facts
Table 128: Daiichi Sankyo Co Ltd: Annual Financial Ratios
Table 129: Daiichi Sankyo Co Ltd: Key Employees
Table 130: Daiichi Sankyo Co Ltd: Key Employees Continued
Table 131: Sawai Group Holdings Co Ltd: Key Facts
Table 132: Sawai Group Holdings Co Ltd: Annual Financial Ratios
Table 133: Sawai Group Holdings Co Ltd: Key Employees
Table 134: Toho Holdings Co Ltd: Key Facts
Table 135: Toho Holdings Co Ltd: Annual Financial Ratios
Table 136: Toho Holdings Co Ltd: Key Employees
Table 137: Towa Pharmaceutical Co Ltd: Key Facts
Table 138: Towa Pharmaceutical Co Ltd: Annual Financial Ratios
Table 139: Towa Pharmaceutical Co Ltd: Key Employees
Table 140: Towa Pharmaceutical Co Ltd: Key Employees Continued
Table 141: Laboratorios Silanes SA de CV: Key Facts
Table 142: Pfizer Inc: Key Facts
Table 143: Pfizer Inc: Annual Financial Ratios
Table 144: Pfizer Inc: Key Employees
Table 145: Pfizer Inc: Key Employees Continued
Table 146: Bluefish Pharmaceuticals AB: Key Facts
Table 147: Bluefish Pharmaceuticals AB: Key Employees
Table 148: AstraZeneca Plc: Key Facts
Table 149: AstraZeneca Plc: Annual Financial Ratios
Table 150: AstraZeneca Plc: Key Employees
Table 151: Navamedic ASA: Key Facts
Table 152: Navamedic ASA: Annual Financial Ratios
Table 153: Navamedic ASA: Key Employees
Table 154: Beacons Pharmaceuticals Pte Ltd: Key Facts
Table 155: Abbott Laboratories SA: Key Facts
Table 156: Adcock Ingram Holdings Ltd: Key Facts
Table 157: Adcock Ingram Holdings Ltd: Key Employees
Table 158: Dongkook Pharmaceutical Co Ltd: Key Facts
Table 159: Dongkook Pharmaceutical Co Ltd: Annual Financial Ratios
Table 160: Dongkook Pharmaceutical Co Ltd: Key Employees
Table 161: JW Holdings Corp: Key Facts
Table 162: JW Holdings Corp: Annual Financial Ratios
Table 163: JW Holdings Corp: Key Employees
Table 164: Hanmi Pharmaceuticals Co Ltd: Key Facts
Table 165: Hanmi Pharmaceuticals Co Ltd: Annual Financial Ratios
Table 166: Hanmi Pharmaceuticals Co Ltd: Key Employees
Table 167: Dong Wha Pharma Co Ltd: Key Facts
Table 168: Dong Wha Pharma Co Ltd: Annual Financial Ratios
Table 169: Dong Wha Pharma Co Ltd: Key Employees
Table 170: Esteve Pharmaceuticals SA: Key Facts
Table 171: Esteve Pharmaceuticals SA: Key Employees
Table 172: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: Key Facts
Table 173: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: Key Employees
Table 174: Deva Holding AS: Key Facts
Table 175: Deva Holding AS: Annual Financial Ratios
Table 176: Deva Holding AS: Key Employees
Table 177: Apotex Inc: Key Facts
Table 178: Apotex Inc: Key Employees
Table 179: Pharmstandard: Key Facts
Table 180: Pharmstandard: Key Employees
Table 181: Biocad: Key Facts
Table 182: Biocad: Key Employees
Table 183: R-Pharm: Key Facts
Table 184: R-Pharm: Key Employees
List of Figures
Figure 1: BRIC generics industry, revenue($m), 2020-29
Figure 2: BRIC generics industry, revenue($m), 2020-24
Figure 3: BRIC generics industry, revenue($m), 2024-29
Figure 4: Brazil generics market value: $ million, 2019-24
Figure 5: Brazil generics market volume: % of total pharma volume, 2019-24
Figure 6: Brazil generics market geography segmentation: % share, by value, 2024
Figure 7: Brazil generics market value forecast: $ million, 2024-29
Figure 8: Brazil generics market volume forecast: % of total pharma volume, 2024-29
Figure 9: Forces driving competition in the generics market in Brazil, 2024
Figure 10: Drivers of buyer power in the generics market in Brazil, 2024
Figure 11: Drivers of supplier power in the generics market in Brazil, 2024
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2024
Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2024
Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2024
Figure 15: China generics market value: $ million, 2019-24
Figure 16: China generics market volume: % of total pharma volume, 2019-24
Figure 17: China generics market geography segmentation: % share, by value, 2024
Figure 18: China generics market value forecast: $ million, 2024-29
Figure 19: China generics market volume forecast: % of total pharma volume, 2024-29
Figure 20: Forces driving competition in the generics market in China, 2024
Figure 21: Drivers of buyer power in the generics market in China, 2024
Figure 22: Drivers of supplier power in the generics market in China, 2024
Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2024
Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2024
Figure 25: Drivers of degree of rivalry in the generics market in China, 2024
Figure 26: India generics market value: $ million, 2019-24
Figure 27: India generics market volume: % of total pharma volume, 2019-24
Figure 28: India generics market geography segmentation: % share, by value, 2024
Figure 29: India generics market value forecast: $ million, 2024-29
Figure 30: India generics market volume forecast: % of total pharma volume, 2024-29
Figure 31: Forces driving competition in the generics market in India, 2024
Figure 32: Drivers of buyer power in the generics market in India, 2024
Figure 33: Drivers of supplier power in the generics market in India, 2024
Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2024
Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2024
Figure 36: Drivers of degree of rivalry in the generics market in India, 2024
Figure 37: Russia generics market value: $ million, 2019-24
Figure 38: Russia generics market volume: % of total pharma volume, 2019-24
Figure 39: Russia generics market geography segmentation: % share, by value, 2024
Figure 40: Russia generics market value forecast: $ million, 2024-29
Figure 41: Russia generics market volume forecast: % of total pharma volume, 2024-29
Figure 42: Forces driving competition in the generics market in Russia, 2024
Figure 43: Drivers of buyer power in the generics market in Russia, 2024
Figure 44: Drivers of supplier power in the generics market in Russia, 2024
Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2024
Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2024
Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security